Serina Therapeutics, Inc. (SER)
1.41
-0.24
(-14.55%)
USD |
NYAM |
Nov 06, 10:31
Serina Therapeutics Enterprise Value : 22.10M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 22.10M |
| November 04, 2026 | 23.11M |
| November 03, 2026 | 26.67M |
| November 02, 2026 | 27.18M |
| October 30, 2026 | 29.46M |
| October 29, 2026 | 28.19M |
| October 28, 2026 | 21.84M |
| October 27, 2026 | 22.60M |
| October 26, 2026 | 23.62M |
| October 23, 2026 | 22.10M |
| October 22, 2026 | 24.89M |
| October 21, 2026 | 25.14M |
| October 20, 2026 | 22.35M |
| October 19, 2026 | 22.10M |
| October 16, 2026 | 23.87M |
| October 15, 2026 | 25.65M |
| October 14, 2026 | 23.62M |
| October 13, 2026 | 26.41M |
| October 12, 2026 | 29.46M |
| October 09, 2026 | 30.98M |
| October 08, 2026 | 31.24M |
| October 07, 2026 | 31.24M |
| October 06, 2026 | 32.00M |
| October 05, 2026 | 32.00M |
| October 02, 2026 | 29.97M |
| Date | Value |
|---|---|
| October 01, 2026 | 29.72M |
| September 30, 2026 | 30.98M |
| September 29, 2026 | 33.02M |
| September 28, 2026 | 31.24M |
| September 25, 2026 | 33.27M |
| September 24, 2026 | 34.54M |
| September 23, 2026 | 35.81M |
| September 22, 2026 | 38.86M |
| September 21, 2026 | 38.86M |
| September 18, 2026 | 37.34M |
| September 17, 2026 | 36.57M |
| September 16, 2026 | 35.05M |
| September 15, 2026 | 39.88M |
| September 14, 2026 | 42.42M |
| September 11, 2026 | 36.57M |
| September 10, 2026 | 43.68M |
| September 09, 2026 | 45.46M |
| September 08, 2026 | 43.68M |
| September 04, 2026 | 49.53M |
| September 03, 2026 | 48.51M |
| September 02, 2026 | 46.73M |
| September 01, 2026 | 43.68M |
| August 31, 2026 | 41.65M |
| August 28, 2026 | 42.67M |
| August 27, 2026 | 44.19M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.884B |
| Oncolytics Biotech, Inc. | 52.27M |
| Sangamo Therapeutics, Inc. | 38.97M |
| Sarepta Therapeutics, Inc. | 2.113B |
| Anixa Biosciences, Inc. | 89.83M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.356M |
| Total Expenses (Quarterly) | 6.356M |
| EPS Diluted (Quarterly) | -0.5451 |
| Earnings Yield | -133.2% |
| Normalized Earnings Yield | -158.74 |